Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025)

Candel Therapeutics recorded quarterly Long-Term Debt Repayments of -$4.2 million in Q4 2025, down 69.32% quarter-over-quarter from -$2.5 million in Q3 2025, and down 69.32% year-over-year from -$13.8 million in Q4 2024.

Candel Therapeutics' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at -$4.2 million for Q4 2025.

  • In Q4 2025, Long-Term Debt Repayments fell 69.32% year-over-year to -$4.2 million; the TTM figure through Dec 2025 stood at -$11.7 million (down 27.99% YoY), while the FY2025 annual figure was -$11.7 million, down 27.99% from the prior year.
  • Long-Term Debt Repayments came in at -$4.2 million for Q4 2025 at Candel Therapeutics, down from -$2.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of -$1.7 million in Q1 2024 to a low of -$4.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Candel Therapeutics 449.62 Mn 449.62 Mn - -4.23 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -4.23 Mn
Dec 31, 2025 -4.23 Mn
Sep 30, 2025 -2.50 Mn
Sep 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Mar 31, 2024 -1.67 Mn
Mar 31, 2024 -1.67 Mn